When health care reform passed the House in November, the vote was 220-215. Since that time…[snip]…If [our] math is correct, Democrats have only about 205 votes to pass health care reform. With four empty House seats, they will need 216. Democratic leaders will be working furiously to twist the arms of the 39 Democrats who voted “no” last time. Those who voted “NO” in November, and are likely to vote “NO” again: Dan Boren, Okla. – Boren, who has a very conservative record, will vote no, his spokesman told The Daily Caller. Allen Boyd, Fla. – His office did not… Original Article: Forum: News/Activism

See the article here:
Updated TODAY: Meet the 18 House Dems whose votes matter most on health care

Publisher’s Note: In light of last week’s failed Phase III trial of Medivation’s Alzheimer’s drug, Dimebon, I’ve asked Anavex Chairman Dr. Cameron Durrant to give us an overview of the Alzheimer’s market. Dr. Durrant has held executive positions at major global pharmaceutical companies, including Merck & Co. (NYSE: MRK), GlaxoSmithKline (NYSE: GSK), and Pharmacia Corporation, now part of Pfizer, Inc. (NYSE: PFE). Most recently, Dr. Durrant spent almost three years as Worldwide Vice President, Infectious Diseases, Global Strategic Marketing at Johnson & Johnson (NYSE: JNJ). He has also been CEO of two specialty pharmaceutical companies, PediaMed and Spherics. His article, written exclusively for Wealth Daily readers, is below… Brian Hicks ——————————————————— Alzheimer’s disease (AD) is one of the scourges of modern day health care. There are almost 30 million people worldwide diagnosed with AD — 5 million of them in the United States. That’s the equivalent of almost the entire population of Canada and Finland, respectively. And it is projected to almost quadruple — yes, quadruple  — by 2050, with 120 million people affected and to care for. (That’s the same population as the country of Japan, the tenth most populous country on the planet.) This patient population will equate to 1 in 85 of the world’s total population at that time… Clearly, we are sitting on a health care time bomb. There are many reasons for the increase, including an aging population globally, the baby boomer demographic, and earlier and more accurate diagnosis. Some speculate that there are other causes related to environmental issues including food and/or water chain pollutants and other toxins from our modern lifestyles. Not surprisingly, the pharmaceutical and biotech industry and academia have and continue to put a strong emphasis on developing treatments. Imagine a world where there were drugs which slowed the progression… or, better yet, stopped progression… or even helped reverse the disease and its effects, reverting people back to previous levels of functioning. Imagine, if you will, the Holy Grail — a prevention measure that could stop people from ever developing Alzheimer’s… All of the drugs approved so far though merely address some of the symptoms. None of them alter the progression of the disease and in most cases, the beneficial effects of the drugs wear off after time. The market leader, Aricept, is co-marketed by pharma drug giant Pfizer and by the Japanese company that discovered the drug, Eisai. But Aricept goes off patent this year and the multibillion dollar sales pattern it has built will vanish quickly, as generic versions line up for approval and sale this year. There are three other marketed drugs — Exelon by Novartis; Razadyne by J+J; and Namenda by Forrest — all off patent or coming close to it. So what do pharma behemoths like this do? They invest in their own in-house programs and/or turn to outside small companies, biotechs, start-ups, and academic-types to source innovation. That’s what Pfizer did with Medivation to get rights to Medivation’s drug, Dimebon. Unfortunately, Dimebon just failed its pivotal Phase III study, dashing hopes for patients and their caregivers and dropping about a billion dollars off the Medivation market cap. The stock collapsed by 70% within minutes of the news. More on that debacle shortly. For years, researchers considered the fact that since a buildup in the brain of a substance called amyloid — which is deposited as plaques around neurons (brain cells) — is associated with AD, that this could actually be the …

Here is the original post:
An Overview of the Alzheimer Drug Market

Yep, the bulls will tell you we’ve hit rock bottom. But three longs years and millions of foreclosed homes later, there’s still a “potential wave of foreclosures” headed our way, according to Freddie Mac… just as we’ve been warning since the early days of 2007. Truth is, we’re nowhere near the end of a crisis that could cost us $1.5 trillion. Though, there are two very simple ways to profit, which we’ll talk about soon in our newest Option ARM and Foreclosure report headed your way shortly. For now, though, despite reports suggesting the housing crisis is bottoming out – strengthening home prices and few foreclosure auctions – there is no recovery in sight. Government repayment programs and loan modification programs may show improvement, but they’re just delaying the inevitability of troubled homeowners trying desperately to hold on to property that has dropped by tens of thousands of dollars. Another obstacle for the housing recovery is the number of mortgages that are underwater where borrowers owe more than what the house is worth. This negative equity doesn’t qualify those people for refinancing and even prevents them from selling the home, often resulting in “strategic defaults.” But the most devastating of all could be the coming Option ARM (adjustable rate mortgage) resets of 2010 and beyond. It could easily lead to higher unemployment, housing glut, decreased home values, and the death of the cash-strapped consumer. What do you think will happen to housing when the resets happen? What do you think will happen when monthly payments on a $400,000 mortgage jumps from $1,287 to $2,593? We’ll see even more foreclosures, as Option ARM resets cause a larger number of foreclosures than subprime. Higher unemployment will deteriorate any chance of keeping some homeowners from defaulting. Homeowners will find it acceptable to strategically default on house payments, as it’s just easier for them to just walk away. And it could result in another three million could foreclosure this year alone, partially caused because: People couldn’t afford the properties they bought; Jobs were lost… and is only expected to worsen; And others are just walking away because “it’s not best for their finances… ” These “walk aways” or “strategic defaults” have more than doubled from 588,000 from 2007 to 2008, according to reports. And there will be more, as financial “experts” tout the benefits of walking away from mortgages. Does that sound like a recovery in process to you? Unfortunately, j ust as 2007 and 2008 were the years of subprime woes, this one will go down as the year of Option ARM resets. With

Read more from the original source:
The Truth About Foreclosures…

BY Edgar Sandoval and Rocco Parascandola DAILY NEWS STAFF WRITERS Cops in Brooklyn shot dead a man who pointed an imitation pistol at them in a Monday afternoon confrontation outside an elementary school. Students at Public School 194, in Sheepshead Bay , had been dismissed a half-hour earlier, but some were in a fenced-off area nearby, witnesses said. Police were called to the scene, on Knapp Street, after getting a 911 call about a man with a gun. When uniformed officers from the 61st Precinct arrived at about 3:10 p.m., the 22-year-old suspect pointed the silver gun – inscribed with Zebra-II – at them and refused orders to drop it, police sources said. “We fired three times,” the source said. Maureen Quinn , who lives nearby, said she ran out of her house and “saw a body laying down on the street.” Read more: http://www.nydailynews.com/ny_local/2010/03/08/2010-03-08_cops_shoot_dead_man_pointing_suspected_toy_gun_after_he_refuses_orders_to_drop_i.html#ixzz0heZYLTb2

Here is the original post:
NYPD cops shoot, kill man pointing toy gun after he refuses orders to drop it Read more: http://www.nydailynews.com/ny_local/2010/03/08/2010-03-08_co

_________________________________________ FREE Daily Stock Alerts From DrStockPick.com _________________________________________ DrStockPick.com Watch List! My Picks for Tuesday March 09, 2010 are: ************************************************************** MBST, Mobile Star Corp., MBST.OB MBST Today’s Activity: Last Trade: $0.05 ($0.01 or 25% UP) Volume 164,900 MBST has developed a coin-operated, free-standing karaoke machine. The vending machine provides a unique personal karaoke experience, and is designed by recording studio professionals. MBST’s

Read more:
MBST, IDOI, DrStockPick.com Watch List! for Tuesday March 09, 2010, IDO Security, Inc. and Mobile Star Corp.

New York Daily News | Karachi’s English-language paper ran a photo of a man said to be Gadahn being taken away with a bag on his head.

Read more:
Pakistan Claims to Have Arrested Adam Gadahn

Welcome to the Wealth Daily Weekend Edition — our insights from the week in investing and links to our most-read Wealth Daily and sister publication articles. “Sell! Sell! Sell!” shouted Mad Money man Jim Cramer in March 2007, advising thousands — if not millions — that an FDA advisory panel would vote Dendreon’s treatment unsafe and ineffective. But what did he know? The FDA voted unanimously that the drug was safe and very much effective the next day. Of course, Cramer admitted to his mistake in confusing Provenge with Provaisic, a drug from the movies. But this wasn’t the first time Cramer “made a mistake” with Dendreon… and it wouldn’t be the last. It was September 2005 when Cramer announced news that Dendreon’s Provenge — a possible treatment for prostate cancer — was a flop. Here was a treatment that thousands of men were counting on… and Jim Cramer said the treatment was rejected by the FDA, that it’d never go to market. But Cramer had no idea what he was talking about… Advertisement Beat Big Pharma to the profits on a breakthrough that’s bigger than penicillin Right under the nose of the drug giants, this small American company has developed the genetic key to eradicating the world’s deadliest diseases — influenza, malaria, HIV, and many of the major killer cancers … Get in on this tiny stock before news of their breakthrough “cell-shock” technology gets out — and your chance at 1000 times your money is gone forever. Dendreon hadn’t even submitted an application for the FDA approval for Provenge. In fact, the drug was just making its way through Phase 3 clinical trials at the time. And anyone following Dendreon knew the chances for a favorable advisory panel review were good, as Phase 3 demonstrated that Provenge significantly increased patient survival with minimal side effects. But in April 2009, Cramer announced “I don’t like Dendreon,” shouting that it had no chance of FDA approval. Again, “Sell! Sell! Sell!” This all transpired right before the underlying stock popped from about $6 to $25. ( Options Trading Pit readers banked 338% when this stock ballooned.) According to sources:* On April 28, at 11:22 am — just hours before Dendreon’s triumph in Chicago — an anonymous message board author on Yahoo! Finance posted this message: “HIGH PROBABILITY OF MASSIVE BEAR RAID… DNDN [Dendreon] could easily drop 50% on a massive bear raid…it’s coming today@12:30 pm central. ” Just minutes before 12:30 pm central, Dendreon’s stock price …

More:
How Wall Street Hoses Main Street

Yourself … Your buyer … Your appraiser … And … your country’s tax assessor … Source: Casey’s Daily Dispatch, March 5, 2010. Did you enjoy this post? If so, click here to subscribe to updates to Investment Postcards from Cape …

Read more:
Your house as seen by …

Dr Stock Pick HOT News & Alerts! _________________________________________ FREE Daily Stock Alerts From DrStockPick.com _________________________________________ Saturday March 06, 2010 DrStockPick.com Stock Report! ************************************************************** MBST, Mobile Star Corp., MBST.OB MBST has developed a coin-operated, free-standing karaoke machine. The vending machine provides a unique personal karaoke experience, and is designed by recording studio professionals. MBST’s Mobile Star is easy-to-use and extremely affordable, allowing any individual

Read this article:
MBST, – DrStockPick.com Stock Alert! – Mobile Star’s Potential Sales Projections Increased

PennyOmega.com Hot Stock News & Alerts! ________________________________________ FREE Daily Stock Alerts From PennyOmega.com ________________________________________ Saturday March 06, 2010 PennyOmega.com Stock Report! ************************************************************** MBST, Mobile Star Corp., MBST.OB According to the U.S. Census Bureau, the U.S. population is over 308,800,500. As kids, we would sing a ton of songs, from The Itsy-Bitsy Spider to whatever was on the radio, with little self-consciousness. How often

Follow this link:
MBST, – Just Make Numbers, Mobile Star’s Potential is ENORMOUS – PennyOmega.com Stock Alert!

Dr Stock Pick HOT News & Alerts! _________________________________________ FREE Daily Stock Alerts From DrStockPick.com _________________________________________ Friday March 05, 2010 DrStockPick.com Stock Report! ************************************************************** MBST, Mobile Star Corp., MBST.OB MBST has developed a coin-operated, free-standing karaoke machine. The vending machine provides a unique personal karaoke experience, and is designed by recording studio professionals. Mobile Star is easy-to-use and extremely affordable, allowing any individual to

Read the original here:
MBST, – DrStockPick.com Stock Report! – Open Market for Mobile Star’s Karaoke Vending Machine

This is a hot button issue… many federal workers are going to read statistics about how a number of occupations in the public sector get paid more than their private sector counterparts and they are simply not going to believe it. Clearly, it’s frustrating for both sides. An article today digs a little further into You Asked for it: More Details on Overpaid Federal Workers originally appeared in the Daily Reckoning . The Daily Reckoning, offers a uniquely refreshing, perspective on the global economy, investing, gold, stocks and today’s markets. Its been called “the most entertaining read of the day.”

See original here:
You Asked for it: More Details on Overpaid Federal Workers